Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
The study, presented at the Society of Interventional Radiology Annual Scientific Meeting, marks one of the first to use freezing on large tumors in the breast.
While the American College of Cardiology's annual meeting has historically had a more clinical focus, presentations at this year's conference in Atlanta will spend much more time looking at the business side of things.
Eric Secemsky, MD, from Beth Israel Deaconess Medical Center and Harvard Medical School, says a lack of hands-on training and reimbursement challenges are hindering the adoption of IVUS.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
